v3.25.2
Description of Business and Significant Accounting Policies - Additional Information (Detail)
€ in Millions
1 Months Ended 6 Months Ended
Jun. 27, 2024
Dec. 31, 2023
Jan. 31, 2022
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2025
USD ($)
Segment
Jun. 30, 2025
EUR (€)
Dec. 31, 2024
USD ($)
Jun. 30, 2024
USD ($)
Jul. 01, 2013
USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Percentage of future royalties         1.00%        
Number of operating segment | Segment         1        
Number of reportable segment | Segment         1        
Purchase of available-for-sale securities         $ 88,127,000        
Loss on purchase commitments | €           € 55.2      
Intra-entity sales or transfers         $ 0        
Segment Reporting, CODM, Profit (Loss) Measure, How Used, Description         The key metric utilized by the CODM to assess resource allocation and performance is the Company’s segment net income, which is the same as the consolidated net income reported in the condensed consolidated statements of operations. The CODM also analyzes the Company's consolidated net income to evaluate its return on segment assets and to establish budgets and forecasts.        
Sagard                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Percentage of royalty on net sales         1.00%        
Percentage of royalty on future net sales   1.00%              
Insulin                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Loss on purchase commitments         $ 66,100,000   $ 58,200,000    
Tyvaso DPI                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Percentage of royalty on net sales         10.00%        
Percentage of royalty on future net sales         9.00%        
Percentage of royalty on net revenue         10.00%        
Percentage of future royalties         9.00%        
Maximum | AFREZZA product sales                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Sales return right following product expiration in months         12 months        
Minimum | AFREZZA product sales                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Sales return right following product expiration in months         6 months        
Convertible Promissory Note | Thirona Bio, Inc.                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Increased interest rate 10.00%                
Principal amount               $ 8,000,000  
Purchase of available-for-sale securities     $ 5,000,000 $ 3,000,000          
Milestone Rights Liability | Deerfield                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Contingent liability for milestone payments         $ 5,000,000        
Contingent liability remain payable         $ 600,000       $ 45,000,000
Milestone Rights Liability | Maximum | Deerfield                  
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]                  
Contingent liability for milestone payments                 $ 90,000,000